Paul Stoffels, Worldwide Chairman
Paul Stoffels, M.D.
Worldwide Chairman, Pharmaceuticals
Dr. Paul Stoffels is Worldwide Chairman, Janssen Pharmaceutical Companies of Johnson & Johnson, with responsibility for research and development, business development and global strategy and innovation. In this role, he leads global teams across Janssen to discover and develop new and innovative treatments for unmet medical needs in the therapeutic areas of cardiovascular/metabolic disease, immunology, infectious disease/vaccines, neuroscience and oncology.
Dr. Stoffels studied medicine at the University of Diepenbeek and the University of Antwerp, Belgium, and infectious diseases and tropical medicine at the Institute of Tropical Medicine, also in Antwerp. He began his career as a physician/researcher in Kinshasa, Congo and Kigali, Rwanda, where he focused on HIV/AIDS and infectious diseases. In 1991, he became the head of development for infectious diseases at Janssen Research Foundation in Beerse, Belgium, where he was instrumental in the development of antifungal drugs.
Dr. Stoffels became CEO of Tibotec-Virco in 1997, where under his leadership the company evolved from a technology-based research company into an integrated pharmaceutical R&D organization focused on new drugs and diagnostics for HIV/AIDS and infectious diseases. The organizations were acquired by Johnson & Johnson in 2002, and he continued to lead the organizations, first as President of Tibotec, and later as Company Group Chairman for the Virology franchise and Global Clinical Operations.
From 2006 to 2009, Dr. Stoffels led the CNS and Internal Medicine franchises as Company Group Chairman. Since 2009 and until his current role as Worldwide Chairman, Dr. Stoffels served as Global Head, Johnson & Johnson Pharmaceutical Research & Development.